1,3-dihydroxyacetone dimer | 62147-49-3

• 物质功能分类: 化学试剂 - 有机试剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 英文名称: 1,3-dihydroxyacetone dimer
• 英文别名: dihydroxyacetone dimer；2,5-bis(hydroxymethyl)-1,4-dioxane-2,5-diol；DHA dimer
• CAS: 62147-49-3
• 化学式: C₆H₁₂O₆
• 分子量: 180.158
• InChiKey: KEQUNHIAUQQPAC-UHFFFAOYSA-N

物化性质

• 熔点：
  75-80 °C(lit.)
• 沸点：
  232.96°C (rough estimate)
• 密度：
  1.2805 (rough estimate)
• 溶解度：
  DMSO（少许）、水（少许）
• LogP：
  -0.951 (est)
• 物理描述：
  Hygroscopic, crystalline, white to off-white powder; Sweet, cooling, aroma
• 稳定性/保质期：
  远离氧化物和水分。

计算性质

• 辛醇/水分配系数(LogP)：
  -3.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  99.4
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• TSCA：
  Yes
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• RTECS号：
  UC1645000
• 海关编码：
  2934999090
• 储存条件：
  存放在密封容器中，并置于阴凉、干燥处。储存地点须远离氧化剂，避免接触湿气或水淹。

SDS

Name:	1 3-Dihydroxyacetone Dimer 98% Material Safety Data Sheet
Synonym:	Dihydroxyacetone, Dimer
CAS:	62147-49-3

Section 1 - Chemical Product MSDS Name:1 3-Dihydroxyacetone Dimer 98% Material Safety Data Sheet
Synonym:Dihydroxyacetone, Dimer

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
62147-49-3	1,3-Dihydroxyacetone, Dimer, 98%		unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Hygroscopic (absorbs moisture from the air).The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Do NOT get water inside containers. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation. Do not get water inside containers.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Do not allow contact with water. Keep from contact with moist air and steam.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Store protected from moisture.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 62147-49-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: white to off-white
Odor: sweet, fruity odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 70.00 - 80.00 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: Slightly soluble.
Specific Gravity/Density:
Molecular Formula: C6H12O6
Molecular Weight: 180.16

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, moisture, excess heat.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 62147-49-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1,3-Dihydroxyacetone, Dimer, 98% - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 62147-49-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 62147-49-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 62147-49-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

有机合成；生化研究，作为半乳糖氧化酶的底物，用于人造鞣剂。

反应信息

• 作为反应物：
  描述：

  1,3-dihydroxyacetone dimer 在 硫酸 双氧水 、 4-甲基苯磺酸吡啶 作用下， 反应 24.0h， 生成 2,5-Diethoxy-p-dioxane-2,5-dimethanol O-2¹,O-5¹-bis(diphenyl phosphate)
  参考文献：
  名称：

  磷酸二羟基丙酮的改进合成

  摘要：

  已经开发了用于合成磷酸二羟基丙酮（DHAP）的改进方法。在1,2,4-三唑或四唑存在下，2,5-二乙氧基对二恶烷-2,5-二甲醇（1）与三价磷酸化试剂二苄基-N，N-二乙基亚磷酰胺（DDP）的反应用H 2 O 2氧化得到2，5-二乙氧基-对-二恶烷-2，5-二甲醇-O-2 1 -O-5 1-双（磷酸）四苄酯（2），产率为98％。然后将化合物2在H 2 -Pd / C存在下氢化，中和后得到2,5-二乙氧基-对二恶烷-2,5-二甲醇-O-2 1 -O-5 1-双（磷酸盐）稳定的三钠盐（3），收率84％。用Dowex 50（H +）处理3会生成2当量的DHAP。

  DOI：

  10.1016/s0040-4020(01)81796-8
• 作为产物：
  描述：

  甘油 在 C₃₂H₃₀N₄O₄Pd₂⁽²⁺⁾ 、 对苯醌 作用下， 以 水 、 乙腈 为溶剂， 反应 4.0h， 以58%的产率得到1,3-dihydroxyacetone dimer
  参考文献：
  名称：

  甘油选择性催化氧化为二羟基丙酮

  摘要：

  高选择性和高产率表征了使用催化剂1，以苯醌或空气作为氧化剂将甘油氧化为二羟基丙酮的特征。所提出的机制涉及可逆的钯-醇盐的形成以及钯配合物的营业额限制的再氧化。

  DOI：

  10.1002/anie.201004063
• 作为试剂：
  描述：

  对氰基苄胺 、 1,3-dihydroxyacetone dimer 在 1,3-dihydroxyacetone dimer 作用下， 以81.5的产率得到1-(4-氰基苄基)-2-巯基-5-羟甲基咪唑
  参考文献：
  名称：

  J. Heterocyclic Chem. 2003, 40, 229

  摘要：

  DOI：

文献信息

• [EN] IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS<br/>[FR] IMIDAZOLYL-IMIDAZOLES EN TANT QU'INHIBITEURS DE KINASE
  申请人：GLAXO GROUP LTD

  公开号：WO2011123609A1

  公开（公告）日：2011-10-06

  Disclosed are compounds having the formula: wherein R1A, R1B, R2 and R3 are as defined herein, and methods of making and using the same.

  揭示了具有以下公式的化合物：其中R1A、R1B、R2和R3如本文所定义，并且制备和使用这些化合物的方法。
• [EN] LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES ORIENTANT VERS LE SYSTÈME LYMPHATIQUE
  申请人：ARIYA THERAPEUTICS INC

  公开号：WO2019046491A1

  公开（公告）日：2019-03-07

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，其制药组合物，制备这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所提供的脂质前药或其制药组合物。
• [EN] LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS LIPIDIQUES D'INHIBITEURS DE JAK ET LEURS UTILISATIONS
  申请人：PURETECH LYT INC

  公开号：WO2020176859A1

  公开（公告）日：2020-09-03

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，其药物组成物，生产这种前药和组成物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或状况的方法，例如本文所披露的那些，包括向需要的患者施用所披露的脂质前药或其药物组成物。
• [EN] TREATMENT OF NEURODEGENERATIVE CONDITIONS<br/>[FR] TRAITEMENT D'ETATS NEURODEGENERATIFS
  申请人：BTG INT LTD

  公开号：WO2005018632A1

  公开（公告）日：2005-03-03

  A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of Ϝ-linolenic acid, dihomo-Ϝ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels.

  提供了一种治疗神经退行性疾病患者的方法，包括向该患者施用含有甘油基团和脂肪酸基团的治疗有效剂量的脂质甘油酯，所述脂肪酸基团选自Ϝ-亚麻酸、二油酸和花生四烯酸组成的群体，其特点在于所选的脂肪酸基团附着在甘油基团的sn-2位置。最好的方法是，脂质被施用的持续时间和剂量足以维持或提高患者体内TGF-β1水平至治疗水平。
• Total Synthesis of (+)-Linoxepin by Utilizing the Catellani Reaction
  作者：Harald Weinstabl、Marcel Suhartono、Zafar Qureshi、Mark Lautens

  DOI：10.1002/anie.201302327

  日期：2013.5.10

  Molecular intelligence: The structurally novel lignan (+)‐linoxepin is synthesized in an eight‐step sequence. The enantioselective synthesis features the palladium‐catalyzed Catellani reaction as the key step. In this highly convergent multicomponent reaction, two new carbon–carbon bonds are formed, one of which results from a CH bond functionalization.

  分子智能：结构新颖的木脂素 (+)-linoxepin 以八步序列合成。对映选择性合成以钯催化的 Catellani 反应为关键步骤。在这种高度收敛的多组分反应中，形成了两个新的碳-碳键，其中一个由 C  H 键官能化产生。

表征谱图